Real-world evidence (RWE) is not always readily accepted by agencies responsible for reimbursement and pricing for new pharmaceuticals, despite a large and growing literature base on the principles of how such evidence can and should be used to support Health Technology Assessments (HTA).
In a five article series published in leading health economics and outcomes research (HEOR) journal, Value in Health, Lumanity HEOR Executive Chair, Ron Akehurst, and Senior Director, Linda Murphy, collaborate with other industry experts to identify obstacles to the optimal use of RWE in HTA, and also present detailed solutions.
In coming to their conclusions, the authors consider why the current situation came about, commonality of barriers across multiple geographies, and the practical tools that will be needed to reduce scepticism and drive confidence in the data.
Find links to the full supplement and the individual articles in Value in Health below.
Using Real-World Data in the Health Technology Assessment of Pharmaceuticals
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward
Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers
Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making
The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed
We help our clients identify fit-for-purpose real world data and design studies to generate the strongest evidence to meet stakeholder needs. We can help you to develop a real world evidence strategy; access, acquire and analyze data; and demonstrate safety effectiveness and economic value. To find out more or to speak to our experts, please contact us.